je.st
news
Tag: pharma
J&J buys bowel drug license option from Isis Pharma for $835 million
2015-01-06 03:00:04| Food - Topix.net
Johnson & Johnson will pay Isis Pharmaceuticals Inc up to $835 million for the option to license three drugs targeting autoimmune diseases in the bowel. Isis Pharmaceuticals said it will receive $35 million in an upfront payment and will be eligible to receive royalties on sales of the drugs.
Tags: million
license
option
drug
Pharma and biotech on a roll as drug approvals hit 18-year high
2015-01-01 15:40:45| Biotech - Topix.net
U.S. drug approvals in 2014 hit their highest level in 18 years and recommendations in Europe also came at a rapid rate, driven by expensive new treatments for cancer and rare diseases. After suffering a wave of patent losses on blockbuster products, which peaked two years ago, drugmakers are recovering their ability to bring new medicines to market and productivity is improving.
Record year in pharma deals not enough to sell mature drugs
2014-12-29 08:01:04| Biotech - Topix.net
In a record year for health care acquisitions, some of the largest pharmaceutical companies tried to sell their portfolios of older drugs - and failed. Drug companies have agreed to about $260 billion of deals so far in 2014, the most since at least 2002 and more than twice the volume last year, according to data compiled by Bloomberg.
X-Chem Licenses Cardiovascular Drug Discovery Program To Bayer Pharma AG
2014-12-29 01:28:39| drugdiscoveryonline Home Page
X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, recently announced it has licensed a second drug discovery program to Bayer Pharma AG pursuant to the multi-target collaboration the companies established in July 2012
Tags: program
drug
discovery
licenses
Pharma Stocks Could Be in Deep Trouble in 2015. Here's Why.
2014-12-28 20:11:35| Biotech - Topix.net
Pharmaceutical companies have had some of the best-performing stocks over the last couple of years thanks to an innovation boom that has produced a host of new game-changing drugs, from Gilead Sciences ' revolutionary new cancer treatment Keytruda. Pharma stocks have crushed the broader market in recent years, as shown by the incredible performance of the iShares Nasdaq Biotech Index to favor its newly approved hepatitis C therapy Viekira Pak for genotype 1 patients, over Gilead's competing drugs, appears to mark a sea change in the pharma landscape that could trigger a major reversal in these stocks.
Sites : [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] next »